BACKGROUND: Transmitted drug resistance to antiretrovirals in HIV-1-infected individuals is rising in some regions and could compromise the effectiveness of first-line treatment. It is important to understand the prevalence of resistance to rilpivirine to inform treatment provision. METHODS: A PUBMED/EMBASE search identified analyses of transmitted genotypic resistance to specific non-nucleoside reverse transcriptase inhibitor mutations worldwide. Patients were to be HIV-1-infected and antiretroviral-naive. Rilpivirine mutations assessed were: L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L. Additionally, frequency of resistance mutations were extracted and pooled by HIV subtype from the Stanford HIV drug resistance database. RESULTS: 138 eligible articles from 65 countries were identified (n=64,466). Among these 64,466 samples, 7 of the 9 genotypic rilpivirine mutations had a prevalence <0.1%. Two mutations were more prevalent: E138A/G/K/Q/R (0.7%, 95% CI 0.2, 1.3) and Y181C/I/V (0.3%, 95% CI 0.2, 0.4). Prevalence of E138 rilpivirine-related mutations varied between regions: highest in Latin America/Caribbean (3.6%, 95% CI 1.0, 7.6) and in Europe (3.2%, 95% CI 0.7, 6.9). Pooled results from the Stanford database (n=52,680) correlated with these findings indicating a low prevalence of 8/9 rilpivirine mutations (<0.1%), except for E138A/G/K/Q/R (2.9%, 95% CI 1.8, 4.4). Prevalence of the mutations at E138 varied significantly by HIV subtype and was highest for subtype-C (6.1%), subtype-F (5.1%) and subtype-A (3.3%). CONCLUSIONS: The prevalence of most transmitted rilpivirine-related HIV mutations is generally low in treatment-naive HIV-1-infected individuals (<0.1%). The prevalence of E138A/G/K/Q/R mutations is higher (0.7%) and varies according to geographical region and HIV subtype.
BACKGROUND: Transmitted drug resistance to antiretrovirals in HIV-1-infected individuals is rising in some regions and could compromise the effectiveness of first-line treatment. It is important to understand the prevalence of resistance to rilpivirine to inform treatment provision. METHODS: A PUBMED/EMBASE search identified analyses of transmitted genotypic resistance to specific non-nucleoside reverse transcriptase inhibitor mutations worldwide. Patients were to be HIV-1-infected and antiretroviral-naive. Rilpivirine mutations assessed were: L100I, K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, Y188L, H221Y, F227C and M230I/L. Additionally, frequency of resistance mutations were extracted and pooled by HIV subtype from the Stanford HIV drug resistance database. RESULTS: 138 eligible articles from 65 countries were identified (n=64,466). Among these 64,466 samples, 7 of the 9 genotypic rilpivirine mutations had a prevalence <0.1%. Two mutations were more prevalent: E138A/G/K/Q/R (0.7%, 95% CI 0.2, 1.3) and Y181C/I/V (0.3%, 95% CI 0.2, 0.4). Prevalence of E138rilpivirine-related mutations varied between regions: highest in Latin America/Caribbean (3.6%, 95% CI 1.0, 7.6) and in Europe (3.2%, 95% CI 0.7, 6.9). Pooled results from the Stanford database (n=52,680) correlated with these findings indicating a low prevalence of 8/9 rilpivirine mutations (<0.1%), except for E138A/G/K/Q/R (2.9%, 95% CI 1.8, 4.4). Prevalence of the mutations at E138 varied significantly by HIV subtype and was highest for subtype-C (6.1%), subtype-F (5.1%) and subtype-A (3.3%). CONCLUSIONS: The prevalence of most transmitted rilpivirine-related HIV mutations is generally low in treatment-naive HIV-1-infected individuals (<0.1%). The prevalence of E138A/G/K/Q/R mutations is higher (0.7%) and varies according to geographical region and HIV subtype.
Authors: Amy G Cutrell; Jonathan M Schapiro; Carlo F Perno; Daniel R Kuritzkes; Romina Quercia; Parul Patel; Joseph W Polli; David Dorey; Yongwei Wang; Sterling Wu; Veerle Van Eygen; Herta Crauwels; Susan L Ford; Mark Baker; Christine L Talarico; Marty St Clair; Jerry Jeffrey; C Thomas White; Simon Vanveggel; Kati Vandermeulen; David A Margolis; Michael Aboud; William R Spreen; Jan van Lunzen Journal: AIDS Date: 2021-07-15 Impact factor: 4.632
Authors: Santiago Avila-Ríos; Claudia García-Morales; Margarita Matías-Florentino; Daniela Tapia-Trejo; Bismarck F Hernández-Álvarez; Sumaya E Moreira-López; Carlos J Quant-Durán; Guillermo Porras-Cortés; Gustavo Reyes-Terán Journal: PLoS One Date: 2016-10-13 Impact factor: 3.240
Authors: Roy Moscona; Daniela Ram; Marina Wax; Efrat Bucris; Itzchak Levy; Ella Mendelson; Orna Mor Journal: J Int AIDS Soc Date: 2017-08-10 Impact factor: 5.396
Authors: Kevin Melody; Chandra N Roy; Christopher Kline; Mackenzie L Cottrell; Dwayne Evans; Kathleen Shutt; Pleuni S Pennings; Brandon F Keele; Moses Bility; Angela D M Kashuba; Zandrea Ambrose Journal: J Virol Date: 2020-03-31 Impact factor: 6.549
Authors: Dirk Schürmann; Deanne Jackson Rudd; Andrea Schaeffer; Inge De Lepeleire; Evan J Friedman; Martine Robberechts; Saijuan Zhang; Yang Liu; Bhargava Kandala; Christian Keicher; Martin Däumer; Jörg Hofmann; Jay A Grobler; S Aubrey Stoch; Marian Iwamoto; Wendy Ankrom Journal: J Acquir Immune Defic Syndr Date: 2022-02-01 Impact factor: 3.771
Authors: Anna Kuznetsova; Aleksey Lebedev; Konstantin Gromov; Elena Kazennova; Maurizio Zazzi; Francesca Incardona; Anders Sönnerborg; Marina Bobkova Journal: Clin Case Rep Date: 2022-02-03